載入中
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
前收盤價
US$2.50
−US$0.05 · -1.96%
盤中時間採用ET。市場資料可能有所延遲。
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
日內區間
目前US$2.50
52週區間
目前US$2.50
盤中時間採用ET。市場資料可能有所延遲。
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
日內區間
目前US$2.50
52週區間
目前US$2.50
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CHF） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 357.3萬 CHF | 2730.9萬 CHF | 1480.1萬 CHF | 393.5萬 CHF | — |
| 銷貨成本 | — | 6257萬 CHF | 5460.6萬 CHF | — | — |
| 毛利 | 357.3萬 CHF | −3526.1萬 CHF | −3980.5萬 CHF | 393.5萬 CHF | — |
| 研究與開發 | 5643.6萬 CHF | 6257萬 CHF | 5460.6萬 CHF | 6033.6萬 CHF | 6228.2萬 CHF |
| 銷售、一般及管理費用 | 1165.2萬 CHF | 1143.4萬 CHF | 1057.6萬 CHF | 958.2萬 CHF | 1087.9萬 CHF |
| 營業費用 | 7243.6萬 CHF | 1711.7萬 CHF | 1381.9萬 CHF | 7478.2萬 CHF | 7901萬 CHF |
| 利息收入 | 186.5萬 CHF | 319.6萬 CHF | 104.4萬 CHF | 6.9萬 CHF | 648.5萬 CHF |
| 利息支出 | 19.1萬 CHF | 13.3萬 CHF | 17.6萬 CHF | 35.5萬 CHF | 58.1萬 CHF |
| 折舊和攤銷 | 250.3萬 CHF | 216.2萬 CHF | 221.5萬 CHF | 235.9萬 CHF | 240.6萬 CHF |
| 營業利益 | −6886.3萬 CHF | −5237.8萬 CHF | −5362.4萬 CHF | −7084.7萬 CHF | −7901萬 CHF |
| 淨利 | −7044.7萬 CHF | −5091.6萬 CHF | −5423.3萬 CHF | −7075.3萬 CHF | −7299.6萬 CHF |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.33
上漲空間 233.20%報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB121.12萬0.01%108.2億 USD0.44%US$206.49+3.00%
Dimensional - US Small Cap ETFDFAS32.16萬0.00%338.69億 USD0.31%US$78.35+0.32%
U.S. Micro Cap Portfolio ETFDFMC11.24萬0.00%75.58億 USD0.43%US$57.813+0.20%
U.S. Vector Equity Portfolio ETF Class SharesDXUV4.03萬0.00%61.81億 USD0.26%US$68.28+0.25%
Dimensional - US Core Equity 2 ETFDFAC2.01萬0.00%885.96億 USD0.21%US$45.33+0.49%
Invesco Nasdaq Biotechnology ETFIBBQ1.89萬0.02%1.12億 USD0.19%US$34.62+2.96%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.47萬0.00%455.91億 USD0.17%US$84.44+0.44%
ProShares Ultra Nasdaq BiotechnologyBIB97750.01%9320.36萬 USD1.19%US$110.98+5.68%iShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACInvesco Nasdaq Biotechnology ETFIBBQU.S. Core Equity 1 Portfolio ETF Class SharesDCORProShares Ultra Nasdaq BiotechnologyBIBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
